# Bevacizumab Versus Ranibizumab in Treatment of Macular Edema From Vein Occlusion

> **NCT01428388** · NA · COMPLETED · sponsor: **Barnes Retina Institute** · enrollment: 150 (estimated)

## Conditions studied

- Retinal Vein Occlusion
- Macular Edema

## Interventions

- **DRUG:** Intravitreal injection of bevacizumab
- **DRUG:** Intravitreal injection of ranibizumab (0.5 mg per dose)

## Key facts

- **NCT ID:** NCT01428388
- **Lead sponsor:** Barnes Retina Institute
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09
- **Primary completion:** 2015-10
- **Final completion:** 2015-12
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2017-10-27

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01428388

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01428388, "Bevacizumab Versus Ranibizumab in Treatment of Macular Edema From Vein Occlusion". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01428388. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*